Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Journal of Medical Genetics|June 3, 1999
Phenotypic findings of Cowden syndrome and Bannayan-Zonana syndrome in a family associated with a single germline mutation in PTENJ T Celebi, H C Tsou, F F Chen, et al.
The British Journal of Dermatology|October 18, 2018
Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trialsR G Langley, A W Armstrong, M G Lebwohl, et al.
The Journal of Investigative Dermatology|November 9, 2000
Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor TIMP-2R Fleischmajer, K Kuroda, R Hazan, et al.
The British Journal of Dermatology|March 1, 2018
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3K A Papp, K B Gordon, R G Langley, et al.
Photochemistry and Photobiology|November 24, 1999
p53 mutations in basal cell carcinomas arising in routine users of sunscreensB S Rosenstein, R G Phelps, M A Weinstock, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 18, 2015
Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis surveyP C M van de Kerkhof, K Reich, A Kavanaugh, et al.
The British Journal of Dermatology|June 22, 2021
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-upK A Papp, M G Lebwohl, L Puig, et al.
Journal of the American Academy of Dermatology|May 1, 1986
Importance of complete cutaneous examination for the detection of malignant melanomaD S Rigel, R J Friedman, A W Kopf, et al.
The Journal of Experimental Medicine|September 7, 2000
Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cellsJ R Abrams, S L Kelley, E Hayes, et al.
The British Journal of Dermatology|June 21, 2019
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeksK Reich, R B Warren, L Iversen, et al.
Pageof 4